A head-to-head study comparing two types of androgen-deprivation therapy (ADT) for the treatment of prostate cancer showed there was no difference in the risk of major adverse cardiovascular events ...
FDA has approved the trade name Firmagon for degarelix for injection, a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate cancer. “This ...
*Localized: T 1/2, NX or N0, and M0. ‡ Locally advanced: T3/4, NX or N0, and M0, or N1 and M0. ITT: Intention to treat; PSA: Prostate-specific antigen. Reproduced ...
Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group Premenopausal women with ...
Ferring Pharmaceuticals announced the launch of a Phase 3b clinical trial of degarelix (gonadotropin-releasing hormone receptor antagonist) for injection as an intermittent androgen deprivation ...
FDA approves Mozobil for non-Hodgkin lymphoma and myeloma, and Degarelix for advanced prostate cancer. The Food and Drug Administration approved Mozobil (plerixafor) in December for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results